Max Healthcare Institute Limited announced that its Chairman and Managing Director will participate in IIFL's Invest India Conference & Capital Day 2026. The disclosure confirms the leadership's engagement with investors at the international event scheduled for June 23, 2026, in London. The company stated that no unpublished price sensitive information would be shared during the conference.

The meeting will be conducted in physical mode, featuring both one-on-one and group interactions. The venue for the event is Hotel Hilton, Paddington, London. The schedule remains subject to changes based on exigencies faced by the investors or the company.

The disclosure was submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dhiraj Arora, Executive Vice President - Company Secretary and Compliance Officer, signed the filing on June 17, 2026.

This information will also be available on the company's official website.

Citi has reiterated its Buy rating on max healthcare institute , setting a target price of ₹1,240. The brokerage views the current levels as an attractive entry point following an 18% correction in the stock, supported by a robust fundamental outlook and a strong balance sheet.

Key Investment Thesis

Citi's positive stance is anchored on a combination of capacity-driven growth and improving business mix. The brokerage projects a 20% EBITDA CAGR through FY26–30E, underpinned by new capacity additions that are expected to progressively contribute to earnings over the forecast period.

Growth Drivers and Revenue Outlook

Revenue acceleration is anticipated from FY27–28, supported by the following key factors:

• Capacity ramp-up from new facilities coming online
• Oncology recovery contributing to improved volumes and revenues
• Better payer mix enhancing overall revenue quality

These drivers are expected to translate into meaningful top-line growth as the company's expanded infrastructure reaches optimal utilisation levels.

Upside Optionality

Beyond the base case, Citi identifies the potential reversal of CGHS oncology pricing as an additional upside optionality for Max Healthcare Institute. A favourable change in CGHS oncology pricing could provide a further boost to revenues and profitability, though this remains contingent on policy developments.

Summary

Citi's maintained Buy rating on Max Healthcare Institute with a ₹1,240 target price reflects confidence in the company's capacity-led growth trajectory. The 18% stock correction is seen as an opportunity, with a 20% EBITDA CAGR projected through FY26–30E, revenue acceleration expected from FY27–28, and CGHS oncology pricing reversal as a potential additional catalyst.